The estimated Net Worth of Bonnie H Anderson is at least $8.36 Million dollars as of 14 April 2023. Ms Anderson owns over 34,000 units of Veracyte Inc stock worth over $2,324,968 and over the last 11 years she sold VCYT stock worth over $4,781,278. In addition, she makes $1,252,000 as Co-Founder & Exec. Chairwoman at Veracyte Inc.
Ms has made over 60 trades of the Veracyte Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently she exercised 34,000 units of VCYT stock worth $190,740 on 14 April 2023.
The largest trade she's ever made was selling 121,917 units of Veracyte Inc stock on 5 August 2022 worth over $3,360,033. On average, Ms trades about 12,797 units every 34 days since 2014. As of 14 April 2023 she still owns at least 76,681 units of Veracyte Inc stock.
You can see the complete history of Ms Anderson stock trades at the bottom of the page.
Bonnie H. Anderson is the Co-Founder & Exec. Chairwoman at Veracyte Inc.
As the Co-Founder & Exec. Chairwoman of Veracyte Inc, the total compensation of Ms Anderson at Veracyte Inc is $1,252,000. There are no executives at Veracyte Inc getting paid more.
Ms Anderson is 63, she's been the Co-Founder & Exec. Chairwoman of Veracyte Inc since . There are 1 older and 8 younger executives at Veracyte Inc. The oldest executive at Veracyte Inc is Dr. Tina S. Nova Ph.D., 67, who is the Pres of CLIA U.S. Bus..
Over the last 11 years, insiders at Veracyte Inc have traded over $201,983,044 worth of Veracyte Inc stock and bought 75,122 units worth $1,149,322 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Nicole Vitullo, and Jesse I Treu. On average, Veracyte Inc executives and independent directors trade stock every 20 days with the average trade being worth of $804,905. The most recent stock trade was executed by John Leite on 4 September 2024, trading 5,479 units of VCYT stock currently worth $163,165.
veracyte is a pioneering genomic diagnostics company. our tests are dramatically improving clinical outcomes for patients by resolving inconclusive results from traditional diagnostic methods. we ask the right questions to resolve ambiguity and bring assurance to light, rendering tens of thousands of costly and unnecessary surgeries truly unnecessary. we are giving patients a clearer path forward. through scientific rigor we employ the best tools, best science and best minds to create tests that enable a more accurate diagnosis without the need for risky, costly and often unnecessary surgery. veracyte consistently brings to bear evidence that is unprecedented in genomic tests, thereby changing today's clinical practice standards. we are making a difference in the lives of physicians and patients. we are doing something real. .
Veracyte Inc executives and other stock owners filed with the SEC include: